On January 10, 2022, Amador Bioscience announced the appointment of Dr. Meina Liang, PhD, a world-renowned innovative drug R&D and bioanalysis expert, as Chief Technology Officer, reporting to Chairman and CEO, Dr. Bing Wang. Dr. Liang will lead Amador’s laboratory department and will establish a cutting-edge bioanalytical technology platform to further strengthen Amador’s ability to provide an international standard to the global pharma industry.
“We are very pleased to welcome Dr. Liang to join us,” said Dr. Wang.
“Dr. Liang has more than 30 years of international industry experience and is a world-renowned expert in the development of small molecule drugs and biomedicine. She is an outstanding leader with a global vision and rich experience in leading global bioanalytical institutions. I believe that under Dr. Liang’s leadership, Amador’s laboratory services will be further improved to maintain our commitment to quality and customer efficiency.”
“Amador is building an industry-leading CRO with cutting-edge technology and comprehensive capabilities , and I’m very excited to be a part of it,” said Dr. Liang, “My entire career has focused on leveraging cutting-edge technologies to solve complex problems in new drug development. This is exactly what Amador is doing now.
Presently, the global innovative drug field is developing rapidly and needs the support of new ideas and new technologies. I am honored to join this team of many brilliant scientists dedicated to innovation in the industry, and very much looking forward to the future we create together.”
Dr. Liang has extensive experience in new drug development and global regulatory filings. Before joining Amador, she was the Executive Director and Global Head of the Bioanalytical Division of AstraZeneca, leading hundreds of laboratory team members to support its large and small molecule drug products in different disease areas from discovery to launch. There, Dr. Liang played a key role in the successful approval of many drugs.
Before joining AstraZeneca, Dr. Liang held technical and management positions at Berlex Biosciences (a US affiliate of Schering AG), Abgenix (now Amgen), and MedImmune.
Dr. Liang is the owner of more than a dozen invention patents, the author of more than 60 peer-reviewed articles, and the organizer and guest speaker of many international industry conferences. She has been invited many times to participate in the US pharmaceutical industry working group to develop industry guidance documents.
Dr. Liang received her Bachelor of Pharmacy from Peking University and her PhD in Pharmacology from the University of North Carolina at Chapel Hill.